FATE News and Press, Fate Therapeutics Inc. From 05/13/21

4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study Continued in Remission without Further Therapeutic Intervention at 6-month Foll...

Image source: The Motley Fool. Fate Therapeutics Inc (NASDAQ: FATE) Q1 2021 Earnings Call May 5, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript

Fate Therapeutics, Inc. (FATE) Q1 2021 Earnings Conference Call May 5, 2021 17:00 ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Senior Vice President, Clinical development Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research and Developm...

ARKG’s Sharpe Ratio and outperformance suggest great stock-picking by the fund manager. However, the neutral rating is premised on a long-term time horizon for value realization in view of ARKG’s rich valuation. Furthermore, the general market is not unequivocally ri...

Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total return of 187.1%, an active return o...

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced ...

Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline Company to Host Investor Event on May 13 to Highlight Interim Phase 1 Clinical Data from the Company’s FT516 and FT538 Programs for Relapsed / Refractory AML SAN DIEGO, April 27, 202...

The anticipated impact on healthcare in a post-pandemic setup has led to contrasting views on two different healthcare providers: HCA Healthcare and LHC Group. Furthermore, several initiations are also included in today’s analyst action.HCA Healthcare downgraded at CitiCiti analysts Ra...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. From 1/2/2016 to date, investing in all 50 stocks, equally weighted, would have produced a total return of 198.2%, an active ret...

Cathie Wood is betting on a genomic revolution because she believes it will be the next big industry disrupting development. We believe Wood’s favorite stocks, Vertex Pharmaceuticals Incorporated (VRTX) and Incyte Corporation (INCY), have attractive upside potential and are ideal inves...